What is MiMedx Group, Inc's earnings per share (EPS)?

MiMedx Group, Inc (MDXG) reported diluted earnings per share of $0.32 for fiscal year 2025. This represents a 14.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

MiMedx Group, Inc (MDXG) Financials

MDXG

Trailing 12 months to June 30, 2026

Revenue $355.2M -2.4% YoY

Net Income $6.2M -80.6% YoY

EPS (Diluted) $0.04 -81.0% YoY

Operating Cash Flow $46.1M -20.6% YoY

Market Cap $672.8M as of Oct 8, 2026

Price / Sales 1.9x on $355.2M revenue, trailing 12 months to June 30, 2026

Price / Earnings 108x on $6.2M net income, trailing 12 months to June 30, 2026

Price / Book 3.1x on $216.0M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 29, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MDXG SEC filings page.

MiMedx Group, Inc (MDXG) reported $355.2M in revenue over the twelve months to Jun 30, 2026, down 2.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MDXG FY2025 2026-10-03

MiMedx has shifted from losses and thin equity to profitable growth financed increasingly by internal cash and a lighter debt burden.

Cash conversion improved materially: operating cash flow moved ahead of net income in FY2024 and stayed there in FY2025, reversing FY2023’s weaker conversion. That pattern suggests reported earnings are increasingly arriving as cash rather than remaining tied up in working capital or noncash items.

Scale is lifting operating profit, but not continuously expanding margins. Gross margin remained near 83%, while operating margin improved from 11.6% in FY2023 to 16.9% in FY2024, then eased to 15.3% in FY2025 as selling, general and administrative expense reached $266.2M.

The financing structure became substantially less dependent on creditors. Debt-to-equity declined from 0.3x to 0.1x between FY2023 and FY2025, while the current ratio rose from 3.6x to 4.3x; together, those measures indicate stronger short-term asset coverage and a larger equity cushion, not just higher reported profit.

Financial Health Signals

Financial Health Score 75/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of MiMedx Group, Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

MiMedx Group, Inc has an operating margin of 15.3%, meaning the company retains $15 of operating profit per $100 of revenue. This results in a moderate score of 63/100, indicating healthy but not exceptional operating efficiency. This is down from 16.9% the prior year.

Growth

MiMedx Group, Inc's revenue surged 20.0% year-over-year to $418.6M, reflecting rapid business expansion. This strong growth earns a score of 74/100.

Leverage

MiMedx Group, Inc carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.32, MiMedx Group, Inc holds $4.32 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 89/100.

Cash Flow

Returns

MiMedx Group, Inc earns a strong 18.9% return on equity (ROE), meaning it generates $19 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 71/100. This is down from 22.0% the prior year.

Altman Z-Score Safe

7.10

MiMedx Group, Inc scores 7.10, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($672.8M) relative to total liabilities ($86.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

MiMedx Group, Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.52x

For every $1 of reported earnings, MiMedx Group, Inc generates $1.52 in operating cash flow ($74.0M OCF vs $48.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

35.83x

MiMedx Group, Inc earns $35.83 in operating income for every $1 of interest expense ($63.9M vs $1.8M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$64.4M

YoY-34.7%

QoQ+9.1%

5Y CAGR-1.1%

10Y CAGR+1.2%

MiMedx Group, Inc generated $64.4M in revenue in Q2 2026. This represents a decrease of 34.7% from the same quarter a year earlier. Against the prior quarter it is up 9.1%.

EBITDA

-$17.7M

YoY-236.1%

QoQ-16.5%

MiMedx Group, Inc's EBITDA was -$17.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 236.1% from the same quarter a year earlier. Against the prior quarter it is down 16.5%.

Net Income

-$14.8M

YoY-254.3%

QoQ-36.6%

MiMedx Group, Inc reported -$14.8M in net income in Q2 2026. This represents a decrease of 254.3% from the same quarter a year earlier. Against the prior quarter it is down 36.6%.

EPS (Diluted)

-$0.10

YoY-266.7%

QoQ-42.9%

MiMedx Group, Inc earned -$0.10 per diluted share (EPS) in Q2 2026. This represents a decrease of 266.7% from the same quarter a year earlier. Against the prior quarter it is down 42.9%.

Cash & Balance Sheet

Cash & Debt

$135.8M

YoY+14.3%

QoQ-15.0%

5Y CAGR+9.8%

10Y CAGR+19.0%

MiMedx Group, Inc held $135.8M in cash against $15.7M in long-term debt as of Q2 2026.

Shares Outstanding

146M

YoY-1.5%

QoQ-2.1%

5Y CAGR+5.4%

MiMedx Group, Inc had 146M shares outstanding in Q2 2026. This represents a decrease of 1.5% from the same quarter a year earlier. Against the prior quarter it is down 2.1%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

69.0%

YoY-12.1pp

QoQ-1.6pp

5Y change-12.3pp

10Y change-18.1pp

MiMedx Group, Inc's gross margin was 69.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 12.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.6 percentage points.

Operating Margin

-28.7%

YoY-41.2pp

QoQ-1.5pp

5Y change-28.1pp

MiMedx Group, Inc's operating margin was -28.7% in Q2 2026, reflecting core business profitability. This is down 41.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.5 percentage points.

Net Margin

-23.1%

YoY-32.8pp

QoQ-4.6pp

5Y change-20.4pp

10Y change-26.5pp

MiMedx Group, Inc's net profit margin was -23.1% in Q2 2026, showing the share of revenue converted to profit. This is down 32.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.6 percentage points.

Return on Equity

-6.9%

YoY-11.3pp

QoQ-2.4pp

MiMedx Group, Inc's ROE was -6.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 11.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.4 percentage points.

Capital Allocation

R&D Spending

$2.8M

YoY-15.9%

QoQ-32.9%

5Y CAGR-7.3%

MiMedx Group, Inc invested $2.8M in research and development in Q2 2026. This represents a decrease of 15.9% from the same quarter a year earlier. Against the prior quarter it is down 32.9%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

MDXG Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MDXG quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$355.2M	$418.6M+20.0%	$348.9M+8.5%	$321.5M+20.0%	$267.8M+10.7%	$242.0M-2.5%	$248.2M-17.0%	$299.3M-16.7%	$359.1M+11.8%	$321.1M+44.8%	$221.7M+18.4%	$187.3M+58.4%	$118.2M+99.8%	$59.2M+118.8%	$27.1M+248.6%	$7.8M
Cost of Revenue	$75.1M	$73.0M+21.5%	$60.1M+10.0%	$54.6M+13.1%	$48.3M+21.9%	$39.6M+0.8%	$39.3M-8.7%	$43.1M+18.4%	$36.4M+3.3%	$35.2M+13.8%	$30.9M+53.1%	$20.2M+59.5%	$12.7M+35.8%	$9.3M+79.8%	$5.2M+54.5%	$3.4M
Gross Profit	$280.1M	$345.6M+19.7%	$288.8M+8.2%	$266.8M+21.6%	$219.5M+8.5%	$202.4M-3.1%	$208.9M-18.5%	$256.2M-20.6%	$322.7M+12.9%	$285.9M+49.9%	$190.8M+14.2%	$167.1M+58.3%	$105.6M+111.7%	$49.9M+128.0%	$21.9M+396.6%	$4.4M
R&D Expenses	$15.4M	$15.1M+22.3%	$12.3M-2.6%	$12.7M-0.3%	$12.7M+27.9%	$9.9M-15.2%	$11.7M+5.2%	$11.1M-29.3%	$15.8M-11.9%	$17.9M+24.8%	$14.3M+70.5%	$8.4M+19.3%	$7.0M+45.6%	$4.8M+67.9%	$2.9M-3.1%	$3.0M
SG&A Expenses	$255.1M	$266.2M+18.3%	$225.1M+6.6%	$211.1M+1.2%	$208.7M+7.1%	$194.8M+7.6%	$181.0M-8.7%	$198.2M-23.3%	$258.5M+17.4%	$220.1M+26.9%	$173.4M+30.0%	$133.4M+47.4%	$90.5M+95.7%	$46.2M+136.0%	$19.6M+99.0%	$9.8M
Operating Income	$8.8M	$63.9M+8.5%	$58.9M+58.6%	$37.1M+352.0%	-$14.7M-108.9%	-$7.1M+84.5%	-$45.4M-114.5%	-$21.2M-439.2%	-$3.9M-108.5%	$46.2M+5128.8%	$884K-96.4%	$24.4M+243.2%	$7.1M+369.0%	-$2.6M+50.7%	-$5.4M+45.1%	-$9.8M
EBITDA	N/A	$78.8M+21.4%	$64.9M+60.1%	$40.5M+481.3%	-$10.6M-482.7%	-$1.8M+95.3%	-$38.5M-183.9%	-$13.6M-553.7%	$3.0M-94.2%	$52.0M+718.2%	$6.4M-76.6%	$27.1M+193.7%	$9.2M+1073.1%	-$948K+73.0%	-$3.5M+56.0%	-$8.0M
Interest Expense	N/A	$1.8M-54.7%	$3.9M-40.1%	$6.6M+30.2%	$5.0M+201.4%	-$5.0M+37.3%	-$7.9M-68.7%	-$4.7M-993.4%	$527K+705.7%	-$87K-125.7%	$339K+294.2%	$86K+79.2%	$48K+6.7%	$45K-92.4%	$593K+403.3%	$118K
Income Tax	$5.3M	$17.7M+15.6%	$15.3M+141.6%	-$36.8M-17967.0%	$206K-16.6%	$247K+102.0%	-$12.3M-245080.0%	-$5K-100.0%	$26.6M+235.4%	-$19.6M-12770.3%	$155K+103.0%	-$5.2M-721.2%	$832K+732.0%	$100K	$0	$0
Net Income	$6.2M	$48.6M+14.5%	$42.4M-27.2%	$58.2M+292.8%	-$30.2M-193.6%	-$10.3M+79.1%	-$49.3M-92.7%	-$25.6M+14.7%	-$30.0M-146.3%	$64.7M+16496.7%	$390K-98.7%	$29.4M+373.4%	$6.2M+251.3%	-$4.1M+46.3%	-$7.7M+24.8%	-$10.2M
EPS (Basic)	N/A	$0.33+13.8%	$0.29-27.5%	$0.40+221.2%	-$0.33-120.0%	-$0.15+80.5%	-$0.77-220.8%	-$0.24+14.3%	-$0.28-145.9%	$0.61	$0.00-100.0%	$0.28+366.7%	$0.06+250.0%	-$0.04+55.6%	-$0.09	N/A
EPS (Diluted)	$0.04	$0.32+14.3%	$0.28-24.3%	$0.37	-$0.33-120.0%	-$0.15+80.5%	-$0.77	-$0.24+14.3%	-$0.28-150.0%	$0.56	$0.00-100.0%	$0.26+420.0%	$0.05+225.0%	-$0.04+55.6%	-$0.09	N/A
Diluted Shares (Avg)	N/A	150M+0.5%	149M+2.1%	146M	113M+2.3%	110M+1.9%	108M	107M+1.3%	106M-9.1%	116M+3.1%	113M-0.9%	114M+0.3%	113M+17.7%	96M+17.9%	82M+12.7%	72M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$64.4M-34.7%	$59.0M-33.1%	$118.1M+27.1%	$113.7M+35.3%	$98.6M+13.1%	$88.2M+4.1%	$92.9M+7.0%	$84.1M+2.9%
Cost of Revenue	$20.0M+7.0%	$17.4M+4.9%	$19.1M+12.7%	$18.7M+22.2%	$18.7M+25.8%	$16.6M+27.5%	$16.9M+22.2%	$15.3M+3.6%
Gross Profit	$44.4M-44.5%	$41.6M-41.9%	$99.0M+30.3%	$95.0M+38.2%	$79.9M+10.5%	$71.6M-0.1%	$76.0M+4.1%	$68.7M+2.7%
R&D Expenses	$2.8M-15.9%	$4.1M+24.4%	$4.8M+33.4%	$3.7M+26.9%	$3.3M+9.7%	$3.3M+17.1%	$3.6M+46.7%	$2.9M-5.1%
SG&A Expenses	$59.8M-6.8%	$53.2M-11.2%	$73.1M+19.7%	$69.0M+28.9%	$64.2M+15.8%	$60.0M+8.8%	$61.0M+12.3%	$53.5M+1.8%
Operating Income	-$18.5M-249.3%	-$16.0M-294.5%	$21.1M+90.6%	$22.2M+98.8%	$12.4M-47.2%	$8.3M-37.5%	$11.1M-28.6%	$11.2M+0.3%
EBITDA	-$17.7M-236.1%	-$15.2M-270.9%	$34.0M+129.0%	$22.9M+91.7%	$13.0M-46.2%	$8.9M-36.1%	$14.8M-9.0%	$11.9M-0.3%
Interest Expense	N/A	$402K-15.9%	$405K-22.3%	$425K-18.4%	$475K-9.0%	$478K-79.9%	$521K-95.4%	$521K-69.0%
Income Tax	-$2.9M-186.8%	-$4.5M-381.4%	$6.6M+73.3%	$6.1M+72.3%	$3.4M-39.4%	$1.6M-32.3%	$3.8M+110.2%	$3.5M+499.2%
Net Income	-$14.8M-254.3%	-$10.9M-254.6%	$15.2M+104.2%	$16.7M+106.9%	$9.6M-45.4%	$7.0M-24.2%	$7.4M-86.1%	$8.1M-5.1%
EPS (Basic)	-$0.10-242.9%	-$0.07-240.0%	$0.10+100.0%	$0.11+120.0%	$0.07-41.7%	$0.05-16.7%	$0.05-87.5%	$0.05-16.7%
EPS (Diluted)	-$0.10-266.7%	-$0.07-240.0%	$0.10+100.0%	$0.11+120.0%	$0.06-50.0%	$0.05-16.7%	$0.05-86.5%	$0.05-16.7%
Diluted Shares (Avg)	148M-1.0%	148M-0.8%	N/A	150M+0.9%	149M+0.3%	150M-0.2%	N/A	148M-0.9%

MDXG Balance Sheet

MDXG quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$342.7M+29.8%	$263.9M+10.4%	$239.0M+39.4%	$171.4M-8.8%	$187.9M-7.0%	$202.0M+20.9%	$167.2M+36.1%	$122.8M+1.3%	$121.3M+3.4%	$117.3M-13.7%	$135.9M+24.4%	$109.3M+29.0%	$84.7M+140.7%	$35.2M+29.8%	$27.1M
Current Assets	$277.5M+44.6%	$191.9M+16.8%	$164.3M+22.4%	$134.2M-9.6%	$148.5M-7.5%	$160.6M+30.3%	$123.2M+66.4%	$74.0M+51.9%	$48.7M-18.0%	$59.5M-38.2%	$96.3M+12.4%	$85.7M+31.0%	$65.4M+261.5%	$18.1M+162.9%	$6.9M
Cash & Equivalents	$166.1M+59.1%	$104.4M+27.3%	$82.0M+24.3%	$66.0M-24.3%	$87.1M-9.1%	$95.8M+38.7%	$69.1M+53.1%	$45.1M+64.2%	$27.5M-9.4%	$30.3M+15.3%	$26.3M-43.5%	$46.6M+5.7%	$44.1M+552.6%	$6.8M+64.2%	$4.1M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$3.0M-47.8%	$5.8M	$0	$0	$0
Inventory	$25.3M+6.4%	$23.8M+13.3%	$21.0M+59.5%	$13.2M+15.8%	$11.4M+9.9%	$10.4M+13.8%	$9.1M-43.1%	$16.0M+68.9%	$9.5M-40.4%	$15.9M+112.8%	$7.5M+45.3%	$5.1M+32.3%	$3.9M+28.4%	$3.0M+324.2%	$713K
Accounts Receivable	$75.7M+35.6%	$55.8M+3.6%	$53.9M+25.0%	$43.1M+6.8%	$40.4M+13.9%	$35.4M+9.6%	$32.3M	$0-100.0%	$64.8M+3262.7%	$1.9M-96.4%	$53.8M+101.5%	$26.7M+65.7%	$16.1M+110.3%	$7.7M+304.5%	$1.9M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M-2.7%	$20.0M0.0%	$20.0M0.0%	$20.0M0.0%	$20.0M-1.1%	$20.2M+400.1%	$4.0M0.0%	$4.0M0.0%	$4.0M0.0%	$4.0M0.0%	$4.0M
Total Liabilities	$86.1M+21.6%	$70.8M-26.5%	$96.3M-49.1%	$189.4M+0.8%	$187.8M-7.1%	$202.2M+52.3%	$132.8M+81.4%	$73.2M+54.2%	$47.5M-31.4%	$69.2M-31.6%	$101.2M+407.7%	$19.9M+79.1%	$11.1M-26.7%	$15.2M-0.2%	$15.2M
Current Liabilities	$64.3M+40.9%	$45.6M-0.9%	$46.0M+5.6%	$43.6M+2.8%	$42.4M-28.4%	$59.2M-12.1%	$67.3M-5.9%	$71.5M+56.2%	$45.8M-24.6%	$60.8M+127.0%	$26.8M+45.5%	$18.4M+91.5%	$9.6M+91.5%	$5.0M+6.0%	$4.7M
Non-Current Liabilities	$21.8M-13.4%	$25.2M-49.9%	$50.3M-65.5%	$145.9M+0.3%	$145.5M+1.7%	$143.0M+118.5%	$65.4M+3885.7%	$1.6M-0.4%	$1.6M-80.4%	$8.4M-88.7%	$74.4M+4776.3%	$1.5M+0.5%	$1.5M-85.1%	$10.2M-3.0%	$10.5M
Long-Term Debt	$16.5M-7.6%	$17.8M-62.9%	$48.1M-1.0%	$48.6M+1.0%	$48.1M+0.9%	$47.7M-23.0%	$61.9M	$0	N/A	N/A	N/A	N/A	$0-100.0%	$4.0M+46.2%	$2.7M
Total Equity	$256.5M+32.9%	$193.1M+35.3%	$142.7M+893.4%	-$18.0M-22036.6%	$82K+154.7%	-$150K-100.4%	$34.4M-30.7%	$49.7M-32.7%	$73.8M+53.5%	$48.1M+38.4%	$34.7M-61.1%	$89.3M+21.4%	$73.6M+267.7%	$20.0M+68.2%	$11.9M
Retained Earnings	-$42.7M+53.2%	-$91.3M+31.7%	-$133.7M+30.3%	-$191.9M-18.7%	-$161.7M-6.8%	-$151.4M-48.3%	-$102.1M-33.4%	-$76.6M-64.4%	-$46.6M+58.2%	-$111.3M-191.9%	-$38.1M+43.6%	-$67.6M+8.4%	-$73.8M-5.9%	-$69.7M-12.4%	-$62.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$281.0M-3.5%	$308.7M+14.1%	$342.7M+29.8%	$319.0M+30.8%	$291.1M+26.5%	$270.4M+22.0%	$263.9M+10.4%	$243.9M+29.0%
Current Assets	$205.4M-7.0%	$240.3M+20.1%	$277.5M+44.6%	$254.1M+47.6%	$220.9M+43.4%	$200.1M+44.1%	$191.9M+16.8%	$172.1M+11.4%
Cash & Equivalents	$135.8M+14.3%	$159.8M+50.1%	$166.1M+59.1%	$142.1M+60.0%	$118.9M+72.2%	$106.4M+119.5%	$104.4M+27.3%	$88.8M+9.4%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$20.9M-15.9%	$26.2M+9.0%	$25.3M+6.4%	$26.5M+9.3%	$24.9M-0.7%	$24.1M-1.6%	$23.8M+13.3%	$24.2M+27.2%
Accounts Receivable	$41.3M-40.3%	$46.0M-26.1%	$75.7M+35.6%	$78.2M+44.7%	$69.2M+31.1%	$62.3M+9.2%	$55.8M+3.6%	$54.0M+10.3%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%
Total Liabilities	$65.0M-12.7%	$65.7M-2.8%	$86.1M+21.6%	$80.0M+27.3%	$74.5M+19.9%	$67.6M+2.6%	$70.8M-26.5%	$62.9M-66.5%
Current Liabilities	$38.5M-23.4%	$44.5M+4.5%	$64.3M+40.9%	$57.7M+37.5%	$50.3M+25.7%	$42.6M+0.9%	$45.6M-0.9%	$41.9M-3.9%
Non-Current Liabilities	$26.5M+9.5%	$21.2M-15.3%	$21.8M-13.4%	$22.4M+6.8%	$24.2M+9.3%	$25.0M+5.5%	$25.2M-49.9%	$20.9M-85.5%
Long-Term Debt	$15.7M-8.7%	$16.1M-8.2%	$16.5M-7.6%	$16.8M-6.5%	$17.2M-5.7%	$17.5M-5.0%	$17.8M-62.9%	$18.0M-63.2%
Total Equity	$216.0M-0.3%	$242.9M+19.8%	$256.5M+32.9%	$238.9M+32.0%	$216.6M+28.9%	$202.8M+30.2%	$193.1M+35.3%	$181.0M+13509.6%
Retained Earnings	-$68.4M+8.4%	-$53.5M+36.4%	-$42.7M+53.2%	-$57.9M+41.4%	-$74.6M+30.1%	-$84.2M+32.3%	-$91.3M+31.7%	-$98.7M+47.3%

MDXG Cash Flow Statement

MDXG quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$46.1M	$74.0M+11.8%	$66.2M+147.2%	$26.8M+249.6%	-$17.9M-802.8%	-$2.0M+93.5%	-$30.3M+23.2%	-$39.4M-210.1%	$35.8M-43.1%	$62.9M+163.9%	$23.8M+26.8%	$18.8M+11.9%	$16.8M+6016.2%	-$284K+91.5%	-$3.3M+50.0%	-$6.7M
Depreciation & Amortization	N/A	$14.9M+146.3%	$6.0M+76.3%	$3.4M-16.3%	$4.1M-21.7%	$5.2M-23.8%	$6.9M-9.6%	$7.6M+9.7%	$6.9M+20.0%	$5.8M+5.4%	$5.5M+100.2%	$2.7M+28.6%	$2.1M+25.7%	$1.7M-8.3%	$1.8M+3.5%	$1.8M
Stock-Based Compensation	N/A	$16.4M-3.2%	$16.9M-0.2%	$17.0M+49.7%	$11.3M-20.0%	$14.2M-7.8%	$15.4M+27.3%	$12.1M-18.3%	$14.8M-30.3%	$21.2M+19.5%	$17.7M+4.9%	$16.9M+47.5%	$11.5M+90.6%	$6.0M+136.7%	$2.5M+53.0%	$1.7M
Capital Expenditures	N/A	N/A	N/A	$2.0M+31.2%	$1.5M-53.0%	$3.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	$24.8M+227.7%	-$19.4M-273.2%	-$5.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$11.9M	-$6.9M+28.1%	-$9.6M-344.7%	-$2.2M+19.0%	-$2.7M+21.6%	-$3.4M+25.5%	-$4.6M-1003.8%	$504K+105.5%	-$9.2M-70.8%	-$5.4M+53.8%	-$11.7M-1622.4%	-$678K+94.4%	-$12.2M-301.6%	-$3.0M-375.0%	-$637K+9.3%	-$703K
Financing Cash Flow	-$17.3M	-$5.4M+84.2%	-$34.2M-299.1%	-$8.6M-1377.6%	-$580K+82.7%	-$3.4M-105.4%	$61.6M-2.1%	$62.9M+803.6%	-$8.9M+85.2%	-$60.4M-640.9%	-$8.2M+77.5%	-$36.2M-1588.0%	-$2.1M-105.3%	$40.6M+514.7%	$6.6M-34.8%	$10.1M
Share Buybacks	N/A	$0	$0-100.0%	$9.5M	$0	$0-100.0%	$900K	$0-100.0%	$7.6M-88.9%	$68.3M+556.7%	$10.4M-74.1%	$40.1M	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$10.0M-169.5%	$1.9M-64.5%	$25.0M+32.9%	$29.3M+49.5%	$14.4M-33.9%	$5.3M-11.4%	$18.8M+83.1%	$19.6M+53.4%
Depreciation & Amortization	$732K+11.2%	$829K+26.2%	$12.9M+241.3%	$684K-11.4%	$658K-12.0%	$657K-12.0%	$3.8M+370.6%	$772K-8.4%
Stock-Based Compensation	N/A	-$1.7M-139.8%	N/A	N/A	N/A	$4.3M-1.8%	N/A	N/A
Investing Cash Flow	-$635K+28.4%	-$5.6M-1289.7%	-$335K+87.9%	-$5.3M-4753.1%	-$887K+2.0%	-$406K+93.3%	-$2.8M-475.3%	$113K+117.4%
Financing Cash Flow	-$13.3M-1114.3%	-$2.6M+10.2%	-$583K-45.8%	-$857K-3274.1%	-$1.1M-204.7%	-$2.9M+91.4%	-$400K+95.5%	$27K-92.7%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

MDXG Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MDXG quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	82.6%-0.2pp	82.8%-0.2pp	83.0%+1.0pp	82.0%-1.7pp	83.6%-0.5pp	84.2%-1.4pp	85.6%-4.3pp	89.9%+0.8pp	89.0%+3.0pp	86.1%-3.2pp	89.2%-0.1pp	89.3%+5.0pp	84.2%+3.4pp	80.8%+24.1pp	56.7%
Operating Margin	15.3%-1.6pp	16.9%+5.3pp	11.6%+17.1pp	-5.5%-2.6pp	-2.9%+15.4pp	-18.3%-11.2pp	-7.1%-6.0pp	-1.1%-15.5pp	14.4%+14.0pp	0.4%-12.6pp	13.0%+7.0pp	6.0%+10.5pp	-4.5%+15.3pp	-19.8%	-125.8%
Net Margin	11.6%-0.6pp	12.2%-6.0pp	18.1%+29.4pp	-11.3%-7.0pp	-4.3%+15.6pp	-19.9%-11.3pp	-8.6%-0.2pp	-8.3%-28.5pp	20.2%+20.0pp	0.2%-15.5pp	15.7%+10.5pp	5.3%+12.2pp	-7.0%+21.4pp	-28.3%	-131.4%
Return on Equity	18.9%-3.0pp	22.0%-18.8pp	40.8%	N/A	-12542.7%	N/A	-74.4%-14.0pp	-60.4%-148.1pp	87.7%+86.9pp	0.8%-84.0pp	84.8%+77.8pp	7.0%+12.6pp	-5.6%+32.7pp	-38.3%+47.4pp	-85.7%
Return on Assets	14.2%-1.9pp	16.1%-8.3pp	24.4%+42.0pp	-17.6%-12.1pp	-5.5%+18.9pp	-24.4%-9.1pp	-15.3%+9.1pp	-24.4%-77.8pp	53.4%+53.1pp	0.3%-21.3pp	21.7%+16.0pp	5.7%+10.5pp	-4.9%+16.9pp	-21.8%+15.8pp	-37.6%
Current Ratio	4.32+0.1x	4.21+0.6x	3.57+0.5x	3.08-0.4x	3.51+0.8x	2.71+0.9x	1.83+0.8x	1.030.0x	1.06+0.1x	0.98-2.6x	3.60-1.1x	4.66-2.2x	6.81+3.2x	3.61+2.2x	1.45
Debt-to-Equity	0.060.0x	0.09-0.2x	0.34	N/A	586.91	N/A	1.80+1.8x	0.00-0.6x	0.64-0.8x	1.44-1.5x	2.91+2.7x	0.22+0.2x	0.00-0.2x	0.200.0x	0.23
Asset Turnover	1.22-0.1x	1.320.0x	1.34-0.2x	1.56+0.3x	1.29+0.1x	1.23-0.6x	1.79-1.1x	2.92+0.3x	2.65+0.8x	1.89+0.5x	1.38+0.3x	1.08+0.4x	0.70-0.1x	0.77+0.5x	0.29
FCF Margin	N/A	N/A	7.7%+15.0pp	-7.2%-5.1pp	-2.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	69.0%-12.1pp	70.6%-10.7pp	83.9%+2.1pp	83.5%+1.8pp	81.0%-1.9pp	81.2%-3.4pp	81.8%-2.3pp	81.8%-0.1pp
Operating Margin	-28.7%-41.2pp	-27.2%-36.6pp	17.8%+5.9pp	19.5%+6.2pp	12.6%-14.3pp	9.3%-6.2pp	11.9%-5.9pp	13.3%-0.3pp
Net Margin	-23.1%-32.8pp	-18.4%-26.4pp	12.9%+4.8pp	14.7%+5.1pp	9.8%-10.5pp	8.0%-3.0pp	8.0%-53.6pp	9.6%-0.8pp
Return on Equity	-6.9%-11.3pp	-4.5%-7.9pp	5.9%+2.1pp	7.0%+2.5pp	4.4%-6.0pp	3.5%-2.5pp	3.9%-33.6pp	4.5%-637.2pp
Return on Assets	-5.3%-8.6pp	-3.5%-6.1pp	4.4%+1.6pp	5.3%+1.9pp	3.3%-4.4pp	2.6%-1.6pp	2.8%-19.6pp	3.3%-1.2pp
Current Ratio	5.33+0.9x	5.39+0.7x	4.32+0.1x	4.41+0.3x	4.39+0.5x	4.70+1.4x	4.21+0.6x	4.10+0.6x
Debt-to-Equity	0.070.0x	0.070.0x	0.060.0x	0.070.0x	0.080.0x	0.090.0x	0.09-0.2x	0.10-36.7x
Asset Turnover	0.23-0.1x	0.19-0.1x	0.340.0x	0.360.0x	0.340.0x	0.33-0.1x	0.350.0x	0.34-0.1x

Not reported in any period shown, so not listed: FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
MiMedx Group, Inc MDXG	FY2025	$418.6M	$48.6M	11.6%	$672.8M	75/100
Maravai LifeSciences Holdings, Inc. MRVI	FY2025	$185.7M	-$130.8M	-70.4%	$1.2B	24/100
180 Life Sciences Corp. ATNF	FY2025	$6.5M	-$450.5M	N/A	$1.1B	12/100
Xeris Biopharma Holdings, Inc. XERS	FY2025	$291.8M	$554K	0.2%	$1.8B	37/100
Intellia Therapeutics, Inc NTLA	FY2025	$67.7M	-$412.7M	N/A	$1.7B	65/100
Maze Therapeutics, Inc. MAZE	FY2025	N/A	-$131.1M	N/A	$1.5B	—

Where MiMedx Group, Inc Ranks

Frequently Asked Questions

What is MiMedx Group, Inc's annual revenue?

MiMedx Group, Inc (MDXG) reported $418.6M in total revenue for fiscal year 2025. This represents a 20.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is MiMedx Group, Inc's revenue growing?

MiMedx Group, Inc (MDXG) revenue grew by 20.0% year-over-year, from $348.9M to $418.6M in fiscal year 2025.

Is MiMedx Group, Inc profitable?

Yes, MiMedx Group, Inc (MDXG) reported a net income of $48.6M in fiscal year 2025, with a net profit margin of 11.6%.

What is MiMedx Group, Inc's EBITDA?

MiMedx Group, Inc (MDXG) had EBITDA of $78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does MiMedx Group, Inc have?

As of fiscal year 2025, MiMedx Group, Inc (MDXG) had $166.1M in cash and equivalents against $16.5M in long-term debt.

What is MiMedx Group, Inc's gross margin?

MiMedx Group, Inc (MDXG) had a gross margin of 82.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is MiMedx Group, Inc's operating margin?

MiMedx Group, Inc (MDXG) had an operating margin of 15.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is MiMedx Group, Inc's net profit margin?

MiMedx Group, Inc (MDXG) had a net profit margin of 11.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is MiMedx Group, Inc's return on equity (ROE)?

MiMedx Group, Inc (MDXG) has a return on equity of 18.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is MiMedx Group, Inc's operating cash flow?

MiMedx Group, Inc (MDXG) generated $74.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are MiMedx Group, Inc's total assets?

MiMedx Group, Inc (MDXG) had $342.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does MiMedx Group, Inc spend on research and development?

MiMedx Group, Inc (MDXG) invested $15.1M in research and development during fiscal year 2025.

How many shares does MiMedx Group, Inc have outstanding?

MiMedx Group, Inc (MDXG) had 149M shares outstanding as of fiscal year 2025.

What is MiMedx Group, Inc's current ratio?

MiMedx Group, Inc (MDXG) had a current ratio of 4.32 as of fiscal year 2025, which is generally considered healthy.

What is MiMedx Group, Inc's debt-to-equity ratio?

MiMedx Group, Inc (MDXG) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is MiMedx Group, Inc's return on assets (ROA)?

MiMedx Group, Inc (MDXG) had a return on assets of 14.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is MiMedx Group, Inc's P/E ratio?

MiMedx Group, Inc (MDXG) trades at 108x earnings, its market capitalization divided by net income of $6.2M net income, trailing 12 months to June 30, 2026. The market capitalization is $672.8M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is MiMedx Group, Inc's price-to-sales ratio?

MiMedx Group, Inc (MDXG) trades at 1.9x sales, its market capitalization divided by revenue of $355.2M revenue, trailing 12 months to June 30, 2026. The market capitalization is $672.8M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is MiMedx Group, Inc's Altman Z-Score?

MiMedx Group, Inc (MDXG) has an Altman Z-Score of 7.10, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is MiMedx Group, Inc's Piotroski F-Score?

MiMedx Group, Inc (MDXG) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are MiMedx Group, Inc's earnings high quality?

MiMedx Group, Inc (MDXG) has an earnings quality ratio of 1.52x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can MiMedx Group, Inc cover its interest payments?

MiMedx Group, Inc (MDXG) has an interest coverage ratio of 35.83x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is MiMedx Group, Inc?

MiMedx Group, Inc (MDXG) scores 75 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.